All In Biotech

Drug Trial Radar · NCT05578053

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer: a Multicenter, Observational, Real-world Study

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Sep 13, 2024

Primary completion

Dec 1, 2028

Study completion Dec 1, 2030

Sponsor

Lead sponsor
Hebei Medical University Fourth HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 13, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, observational, real-world study. We planned to recruit 420 HR+ locally advanced or metastatic breast cancer patients who had received or had not received prior systemic therapy. All patients included in the analysis were receiving or planning to receive dalpiciclib-containing regimens without restrictions, completely following the physician 's clinical choice, to assess the efficacy and safety of dalpiciclib-containing regimens.

Conditions

  • Breast Cancer

Interventions

  • DalpiciclibDrug

    a new, orally administered, selective CDK4/6 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: 2 years
  2. AETime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Fourth hospital of Hebei University

    Shijiazhuang, Hebei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.